HomeDiscoveryPipelineMilciclib (PHA-848125/TZLS-201)

Milciclib (PHA-848125/TZLS-201)

Milciclib is an orally-available, small molecule, broad-spectrum inhibitor of cyclin-dependent kinases (CDKs), as well as other protein kinases responsible for controlling tumor cell growth and replication. It was invented and initially developed by NMS, then outlicensed to the UK Biotechnology company Tiziana Life Sciences plc, which is primarily investigating activity of the drug in hepatocellular carcinoma (HCC).